Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox\u2122 platform today announces an exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company for the Middle East and North Africa (MENA) region.<\/p>\n
<\/p>\n
Under the terms of the agreement, Hikma has an exclusive license to commercialize products in Rakuten Medical\u2019s pipeline using its photoimmunotherapy technology platform, Alluminox\u2122, in all its MENA markets.<\/p>\n
<\/p>\n
Commenting on the agreement, Mickey Mikitani, Co-CEO of Rakuten Medical, said: \u201cWe are already developing Alluminox treatment in several countries and regions, including the United States, Japan, Taiwan, and India, and this agreement further accelerates our global expansion. With Hikma’s strong regional footprint and medical expertise, we expect the Alluminox\u2122 platform to make significant progress in MENA.\u201d<\/p>\n
<\/p>\n
Mazen Darwazah, Hikma\u2019s Executive Vice Chairman and President of MENA, added: \u201cThis agreement allows us to work with an excellent global partner to strengthen our growing portfolio in oncology and biotechnology. Most importantly, this allows us to bring a potentially transformative technology to cancer patients in MENA, helping to put better health within reach, everyday.\u201d<\/p>\n
<\/p>\n
<\/p>\n
* Rakuten Medical\u2019s therapies based on Alluminox\u2122 platform are investigational outside of Japan, and not approved in MENA for investigational or commercial use.<\/em><\/p>\n <\/p>\n <\/p>\n About Hikma<\/strong><\/p>\n Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people’s lives. We’re committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,700 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com<\/a><\/p>\n <\/p>\n Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-\/stable S&P and Ba1\/stable Moody\u2019s)<\/p>\n <\/p>\n About Rakuten Medical, Inc.\u00a0<\/strong><\/p>\n Rakuten Medical, Inc. is a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox\u2122 platform, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing and tumor necrosis. Alluminox therapies have not yet been approved outside of Japan. Rakuten Medical is committed to its mission to conquer cancer by delivering our innovative treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 6 countries, including the United States, where it is headquartered, Japan, the Netherlands, Taiwan, Switzerland and India. For more information, visit www.rakuten-med.com<\/a>.<\/p>\n <\/p>\n About Alluminox\u2122 platform\u00a0<\/strong><\/p>\n The Alluminox\u2122 platform is an investigational technology platform based on a cancer therapy called photoimmunotherapy, which was developed by Dr.\u00a0Hisataka Kobayashi\u00a0and team from the National Cancer Institute in\u00a0the United States. Rakuten Medical is developing the Alluminox platform as a technology consisting of a drug, device, and other related components. The drug component of the platform consists of a targeting moiety conjugated with one or more dyes leading to selective cell surface binding.\u00a0The device component consists of a light source that locally illuminates the targeted cells with light to transiently activate the drug.\u00a0Pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted cancer cells and\/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Outside of\u00a0Japan, Alluminox therapies have not yet been approved by any regulatory authority.<\/p>\n <\/p>\n Forward Looking Statements\u00a0<\/strong><\/p>\n This press release contains forward looking statements that correspond to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include various risks, uncertainties, and assumptions that may cause Rakuten Medical\u2019s business plans and results to differ from the anticipated results and expectations expressed in these statements. These \u201cforward looking statements\u201d contain information about the status and development of our products, including the Alluminox\u2122 platform, as well as other regulatory and marketing authorization efforts, the potential benefits, efficacy, and safety of therapies created using the Alluminox platform, and the status of regulatory filings. The approval and commercial success of the product may not be achieved. Forward looking statements relate to the potential benefits, efficacy, and safety of our therapies, and the status of regulatory filings. Such statements may include words such as \u201cexpect,\u201d \u201cbelieve,\u201d \u201chope,\u201d \u201cestimate,\u201d \u201clooks as though,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201csuggest,\u201d \u201cplan,\u201d \u201cstrategy,\u201d \u201cwill,\u201d and \u201cdo\u201d, and are based on our current beliefs. In addition, this press release uses terms such as \u201cimportant,\u201d \u201cnotable,\u201d and \u201cabnormal\u201d to express opinions about clinical trial data. Ongoing clinical trial studies include various risks and uncertainties, in particular, problems that arise during the manufacturing stage of our therapies, the occurrence of adverse safety events, situations in failure to demonstrate therapeutic benefits, and other various risks and uncertainties, both reasonable and unreasonable. For this reason, actual results, including regulatory approvals and uncertainties in the commercialization process of our therapies, may differ from published information. Except to the extent required by applicable law, we undertake no obligation to publicly update this or any other forward-looking statement, whether because of new information, future developments or events, changes in assumptions, changes in the factors affecting forward-looking statements. If one or more forward-looking statement(s) is updated, no inference should be drawn that additional updates will be made to those or other forward-looking statements.<\/p>\n <\/p>\n <\/p>\n